NFKBIA and metabolic dysfunction-associated steatotic liver disease: The results of this study also showed that compared with that in NAFLD group, the expression of NF-κB p65 decreased and that of IκBα increased in the wogonoside-treated groups, further indicating that wogonoside can protect NAFLD mice from the liver injury by regulating the NF-κB pathway and inhibiting the inflammation.